GEMSTONE-302: “If you keep doing the same thing you get the same result”
Article in Chinese Clinical Oncology (December 2022)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC
Article in Journal of Thoracic Oncology (October 2022)